Why Globus Medical Stock Rose 10% on January 9
On January 9, Globus Medical was trading at a stock price of $43.79, which is an ~9.91% rise from its closing price of $39.84 on January 8.
TransEnterix Stock Rose 5.41% after Its Corporate Update
On October 1, TransEnterix stock closed at $5.64, which represents ~344.0% growth from its 52-week low of $1.27 on February 9.
How Wall Street Analysts View TransEnterix
Of the five analysts tracking TransEnterix in July, two of them have recommended a “strong buy,” and one has recommended a “buy.”
Why Mizuho Securities Upgraded Teva Pharmaceutical to a ‘Buy’
On January 9, 2018, Mizuho Securities upgraded Teva Pharmaceutical Industries (TEVA) from a “neutral” to a “buy” rating. It came after Teva announced its business restructuring plan.
Inside Johnson & Johnson’s Orthopedic Medical Devices Performance in 3Q17
In 3Q17, JNJ hip medical devices generated revenues of $328 million, which reflected a ~2% YoY year-over-year rise and a 6% QoQ (quarter-over-quarter) rise.
Stryker Expands Its Interventional Spine Segment
On July 11, 2017, Stryker announced that it received the FDA 510(k) clearance for its MultiGen 2 RF (radio frequency) generator.
Johnson & Johnson’s Expandable Cage Acquisition to Accelerate the Spine Division
On January 3, DePuy Synthes, a subsidiary of Johnson & Johnson (JNJ), entered into an asset purchase and development agreement with Interventional Spine.
Why Did H.B. Fuller’s Construction Products Revenue Fall?
H.B. Fuller’s (FUL) Construction Products segment reported revenue of $64.4 million in 3Q16, which is 12.6% of the company’s total revenue.
Understanding Stryker’s Neurotechnology and Spine Segment
Stryker’s Neurotechnology and Spine segment reported an increase of 5% in net sales in 2014, driven by increased demand for neurotechnology products.
How Economic and Demographic Factors Affect Medical Device Industry
Though the medical device sector displays significant resilience towards changes in the economic environment, economic factors do impact short-term demand substantially.
Nuvasive Traded above Its 100-Day Moving Average
Nuvasive (NUVA) gained 1.3% on October 12, 2015. The stock went up on the news that the FDA gave clearance for NUVA’s cervical corpectomy cage.